Nkarta to Participate in a September Investor Conference

Group 1 - Nkarta, Inc. is participating in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 8:30 a.m. ET, featuring a fireside chat [1] - A simultaneous webcast of the event will be available on Nkarta's website, with a replay archived for approximately 90 days [1] - Nkarta is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases [2] Group 2 - The company utilizes a cell expansion and cryopreservation platform combined with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities [2] - Nkarta aims to build a pipeline of future cell therapies designed for deep therapeutic activity and broad access in outpatient treatment settings [2]